SpringWorks Therapeutics Inc (NAS:SWTX)
$ 34.76 1.66 (5.02%) Market Cap: 2.58 Bil Enterprise Value: 2.10 Bil PE Ratio: 0 PB Ratio: 4.63 GF Score: 40/100

SpringWorks Therapeutics to Discuss The ReNeu Topline Data Transcript

Nov 16, 2023 / 01:30PM GMT
Release Date Price: $20.45 (-7.34%)
Operator

Good morning, ladies and gentlemen, and welcome to the SpringWorks Therapeutics conference call to discuss the Phase 2b ReNeu trial topline results. At this time, I would like to turn the call over to Samantha Sandler, Senior Director of Investor Relations.

Samantha Sandler
SpringWorks Therapeutics, Inc. - Senior Director, IR

Good morning, and thank you for joining us today for the ReNeu trial topline results call. Slides to accompany this conference call will be posted in the Investors & Media section of our website at www.springworkstx.com. And a recording of this webcast will also be made available on our website following this call.

Before we begin, I'd like to remind you that today's discussion will contain forward-looking statements that involve risks and uncertainties and that the company's actual results may differ materially from what is discussed during today's call. For a description of risk factors associated with investing in SpringWorks Therapeutics, please refer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot